Abstract
SARS-CoV-2 infection induces severe disease in a subpopulation of patients, but the underlying mechanisms remain unclear. We demonstrate robust IgM autoantibodies that recognize angiotensin converting enzyme-2 (ACE2) in 18/66 (27%) patients with severe COVID-19, which are rare (2/52; 3.8%) in hospitalized patients who are not ventilated. The antibodies do not undergo class-switching to IgG, suggesting a T-independent antibody response. Purified IgM from anti-ACE2 patients activates complement. Pathological analysis of lung obtained at autopsy shows endothelial cell staining for IgM in blood vessels in some patients. We propose that vascular endothelial ACE2 expression focuses the pathogenic effects of these autoantibodies on blood vessels, and contributes to the angiocentric pathology observed in some severe COVID-19 patients. These findings may have predictive and therapeutic implications.
One-sentence summary ACE2 autoantibodies in severe COVID-19 have features of a T-independent immune response, and may mediate vascular damage.
Competing Interest Statement
Antony Rosen and Livia Casciola-Rosen are listed as inventors on a patent application filed by Johns Hopkins University that encompasses aspects of this publication
Funding Statement
Funding for these studies were provided by the Bill & Melinda Gates Foundation (BMGF), Gates Philanthropy Partners, the Donald and Dorothy Stabler Foundation, and the Jerome L. Greene Foundation. This study was supported in part by NIH grants R01 AR073208 (LCR), R01 AR069569 (FA), NIH IRACDA program (5K12GM123914-03, EKL) and the Division of Intramural Research, National Institutes of Allergy and Infectious Diseases (OL). The Rheumatic Diseases Research Core Center, where the ELISA assays were performed, is supported by NIH P30-AR070254.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These studies were approved by the JHU Institutional Review Board (IRB 00251725, IRB 00256018, 00256547), with a waiver of consent because all specimens and clinical data were de-identified by the Core for Clinical Research Data Acquisition of the Johns Hopkins Institute for Clinical and Translational Research; the study team had no access to identifiable patient data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Patient data and autoantibody data are stored in JH-CROWN, hosted on the Johns Hopkins Precision Medicine Analytics Platform. Data or materials derived from human samples may be requested subject to any underlying restrictions on such data or samples, and will require material transfer and data use agreements through Johns Hopkins University.
Data Availability
Patient data and autoantibody data are stored in JH-CROWN, hosted on the Johns Hopkins Precision Medicine Analytics Platform. Data or materials derived from human samples may be requested subject to any underlying restrictions on such data or samples, and will require material transfer and data use agreements through Johns Hopkins University.
Data Availability
Patient data and autoantibody data are stored in JH-CROWN, hosted on the Johns Hopkins Precision Medicine Analytics Platform. Data or materials derived from human samples may be requested subject to any underlying restrictions on such data or samples, and will require material transfer and data use agreements through Johns Hopkins University.
Data Availability
Patient data and autoantibody data are stored in JH-CROWN, hosted on the Johns Hopkins Precision Medicine Analytics Platform. Data or materials derived from human samples may be requested subject to any underlying restrictions on such data or samples, and will require material transfer and data use agreements through Johns Hopkins University.
